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commonly  followed  by  24  months  rituximab  maintenance  (Salles  et  al,  2008).  Combinations     of 
consolidated with autologous or allogeneic stem-cell transplantation (alloSCT) (Kothari et al, 2014). 
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Follicular lymphoma (FL) is an indolent B-cell malignancy with a variable clinical course. Standard immuno- 
chemotherapy typically incorporate alkylator and anti-CD20 monoclonal antibody as first line (Rummel et al, 
2013) 
 
 
Over time, 
responses to immuno-chemotherapy and length of remissions diminish. Relapsed or refractory (R/R) FL in 
patients unfit for transplantation or post-transplantation is incurable, and remains an unmet clinical need. 
Idelalisib is a potent, small-molecule inhibitor of the phosphatidylinositol 3-kinase δ-isoform (PI3Kδ). The δ- 
isoform is critical for normal B-cell function, signal transduction and important cytokines, chemokines, and 
integrins (Durand et al, 2009). PI3Kδ pathways are constitutively activated in B-cell malignancies (Lannutti et 
al, 2011). 
 
 
 
A phase II (DELTA) trial was performed in double-refractory indolent non-Hodgkin lymphoma (iNHL) (Gopal et 
al 2014). 125 patients (72 FL) received idelalisib 150mg b.d. until progressive disease (PD), unacceptable 
toxicity, or death. 90% were refractory to their prior regimen. All received alkylator and rituximab and a 
median of 4 regimens. The overall response rate (ORR) was 57% (FL 54%). The median duration of response  
was 12·5 months, median progression-free survival (PFS) 11·0 months and overall survival (OS) 20·3 months. 
anthracyclines, purine analogues, and alkylators are used at relapse and younger patients may have remissions 
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Idelalisib was subsequently FDA and EMA approved but not NICE approved. Idelalisib was available in the UK 
and Ireland via the expanded access programme (2015-2016) for double-refractory FL. No data are published 
following DELTA. We investigated the efficacy of idelalisib in a retrospective, multicentre population of R/R FL. 
51 centres were approached (Fig S1), with data collected from 46 sites (01/2015-08/2016). Baseline 
characteristics were collected at commencing idelalisib. Details on prior therapy were collected. 
Refractory disease was defined as stable disease (SD) or PD to the prior treatment, or relapse <6 months 
following a previous partial/complete response (PR/CR) according to DELTA. Relapsed disease followed a 
remission >6 months. Adverse events (AEs) were collected although grading AEs was non-routine. Follow-up 
was censored at the most recent visit or death. The data were locked in 08/2016. 
Patients received idelalisib 150mg b.d. until PD, toxicity or death. PFS and OS were calculated in stand ard 
fashion. Cox regression determined univariate predictors of PFS. Analyses were performed in Stata 14.1 
(StataCorp, College Station, TX). 
 
 
 
The median age was 64 years with an equal gender distribution (Table 1). Our cohort included a larger  
proportion of high FLIPI scores although more patients within DELTA had true refractory disease . Most 
received R-CHOP or R-CVP induction (Table 1S). Second line therapy was typically anthracycline-based or 
bendamustine. 
 
 
 
 
progression (n=35) or stopped due to toxicity without progression (n=2; recurrent grade (G)4 pneumonitis, G3 
diarrhoea). Eight patients received an alloSCT and 2 were planned. 
 
 
 
ORR was 57% (CR/CRu 15%; PR 42%) in 65 assessable. Three developed toxicities and were never radiologically 
assessed, and 11 were awaiting their first radiological assessment (typically cycle 2-4) at censoring. Fig 1(A-E) 
provides the survival outcomes. The median follow-up was 6.1 months (range: 0.1-18.8 months). The  median 
PFS was 7·1 months (95% CI 5·0-9·1 months) (A) and median OS was not-reached (NR) (95% CI 13·7 months- 
24 patients received treatment post-idelalisib. This included 4 biopsy-confirmed or clinically suspected HGT 
(pixantrone (n=2), CHOP-R (n=1), dose-adjusted EPOCH-R (n=1). The remaining 55 either died without  further 
therapy because of PD (n=17) or toxicity (n=1; toxic epidermal necrolysis (TEN)), remained on idelalisib without 
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NR) (B). Patients with lower FLIPI have a non-statistically significant trend towards an improved outcome (C; 
median PFS: 9·3 months (95% CI 6·0 months-NR) vs. 6·6 months (95% CI 3·5-8·4 months), p=0·09). Responders 
had a durable median PFS of 14·1 months (D; 95% CI 8·1 months-NR). There was no difference between the 
PFS of the prior treatment and idelalisib (E; p=0·82). 
Nineteen died from PD, 1 following cytomegalovirus (CMV) pneumonitis, 1 from TEN, 1 of a myocardial 
infarction whilst on pixantrone for HGT, and 1 from ischaemic bowel with otherwise SD. 
 
 
 
There were no predictors of PFS (Table IIS). The best-fitting multivariate model showed a trend towards 
increased PD or death in patients with higher FLIPI (0-2 vs. 3-5, HR 2·09 (95% CI 0·98-4·45, p=0·055) and prior 
rituximab maintenance (HR 1·91, (95% CI 0·96-3·79, p=0·065). 
Idelalisib was generally well tolerated, with no AEs reported in 52 (66%) patients (Table IIIS). This may 
represent some under-reporting of non-clinically significant G1-2 AEs. Commonly reported AEs were non- 
neutropenic infection and bronchial infection. G3-4 diarrhoea/colitis was noted in 5 patients and G3-4 
pneumonitis in 4 patients post 2 cycles (n=3) and 6 cycles (n=1). One was associated with CMV reactivation. 
Idelalisib was stopped permanently in 7 patients due to toxicity (TEN (n=1), G3 diarrhoea (n=2) occurring at   8  
 
 
 
temporary withholding idelalisib and dose attenuation. 
 
 
This is the only real-world series outlining the efficacy and survival of idelalisib-treated R/R FL. Our series 
(n=79) is larger than the trial arm (n=72). The ORR of 57% and PFS of 7·1 months highlights the efficacy of 
idelalisib in R/R FL, with similar responses to DELTA. Responders had durable remissions (median 14·1 
months). A small number proceeded to alloSCT. The median PFS was inferior to DELTA (11 months), 
highlighting the well-described difficulty of extrapolation of trial data into the real world. The PFS curve for 
idelalisib almost overlaps that of the prior therapy and demonstrates the incremental value of idelalisib over 
historical options. 
Recently,   Gilead   closed   three   international   trials   (GS-US-312-0123,   GS-US-313-0124, GS-US-313-0125) 
 
following an increased death and infection rate in the idelalisib arms, with increased PCP and    CMV infection. 
months in both, G3 colitis/bronchial infection (n=1), recurrent G4 pneumonitis (n=1), G3 pneumonitis (n=1), G4 
hepatitis (n=1)), two of whom had not progressed. All other G3-4 AEs were managed with supportive care, 
98 
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The EMA recently confirmed a positive benefit: risk profile for idelalisib monotherapy in R/R FL and retained its 
licence. We report a rate of CMV reactivation, diarrhoea/colitis and pneumonitis consistent with the safety 
data from DELTA. We did not collect data on PCP prophylaxis and CMV monitoring as these recommendations 
post-dated our data collection. 
The weaknesses of our study include the lack of centralised pathology review, formalised radiological 
reporting, prospective AEs reporting, and possible underreporting of G1-2 AEs. However standard UK practice 
mandates clinico-pathological review by a multi-disciplinary team prior to new therapy. 
 
 
 
Obinutuzumab-bendamustine with obinutuzumab maintenance is recently licenced in rituximab-refractory  FL 
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Ibrutinib (ORR 30%) (Bartlett et al, 2014)  and venetoclax  (ORR 27%)  (Seymour       et al,  2014)  show  limited 
monotherapy  activity.  As  such,  idelalisib  remains  the  only  licensed  small-molecule  inhibitor  in  R/R     FL. 
following the GADOLIN trial (Sehn et al, 2016) and will become increasingly available. 
Idelalisib monotherapy is relatively safe and effective in R/R FL. ORR was similar to DELTA, and responses were 
durable. No new safety signals were raised and 10% received a subsequent alloSCT following remission. 
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31 
32 
33 
34 Table I: Baseline Characteristics 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
Characteristics FL patients in the phase II trial 
(n = 72) 
Retrospective cohort 
(n = 79) 
Median age (years) 62 (33-84) 64 (29-86) 
>60 years Not available 51/79 (65%) 
Gender   
Male 39 (54%) 40 (51%) 
Female 33 (46%) 39 (49%) 
ECOG   
0-1 66 (92%) 59 (75%) 
2-4 6 (8%) 20 (25%) 
Median NHL Duration (years, range) 4·7 (0·8–18·4) 4·5 (0·4-24·6) 
Baseline tumour assessment   
Refractory 62 (86%) 41 (54%) 
Relapsed 10 (14%) 35 (46%) 
  3 unclassifiable 
Histology - DLBCL at any time point   
Yes 0 (0%) 7 (9%) 
No 72 (100%) 72 (91%) 
Ann Arbor staging   
1-2 12 (17%) 12 (15%) 
3-4 60 (83%) 67 (85%) 
FLIPI score 
0-2 
 
33 (46%) 
 
19 (25%) 
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22 
23 
24 Abbreviations:  ECOG;  Eastern  Cooperative  Oncology  Group,  DLBCL;  diffuse  large  B  cell  lymphoma,  iNHL; 
25 indolent non-Hodgkin lymphoma, PR; Partial response, CR/CRu; complete response / unconfirmed complete 
26 response, SD; stable disease, PD; progressive disease, ULN; upper limit of normal, CI; confidence interval, FLIPI; 
27 follicular lymphoma international prognostic index, N/S: non-significant. 
28 
29 
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31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
3-5 39 (54%) 59 (75%) 
1 unclassifiable 
Response to most recent chemotherapy 
CR/CRu 
PR 
SD 
PD 
 
Not available 
 
19 
29 
16 
13 
2 unavailable 
Median time from last chemotherapy 
to idelalisib (months, range) 
Not available 8·6 (0·9-99·2) 
Median number of previous 
chemotherapy regimens (number, range) 
4 (2-12) 3 (1-13) 
Prior rituximab 
Prior rituximab maintenance 
Prior alkylator 
72 (100%) 
Not available 
72 (100%) 
78 (99%) 
51 (65%) 
79 (100%) 
Previously received stem-cell 
transplantation 
Yes 
No 
 
12 (17%; all autologous) 
60 (83%) 
 
21 (27%; 4 allogenic, 16 autologous, 1 both) 
58 (73%) 
Idelalisib treatment duration 
(months, range) 
Treatment duration median 6—5 
(0—6–31—0) 
Treatment duration median 4·3 (0·1–18·8) 
 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
 
 
Abbreviations: CHOP+/-R; cyclophosphamide, doxorubicin, vincristine, prednisolone, rituximab, CVP+/-R; rituximab, 
cyclophosphamide, vincristine, prednisolone, ICE; ifosfamide, carboplatin, etoposide, GEM; gemcitabine, DHAP; 
dexamethasone, high dose cytarabine, cisplatin; ESHAP; etoposide, high dose cytarabine, methylprednisolone, cisplatin, IVE; 
ifosfamide, epirubicin, etoposide, RT; radiotherapy, B; bendamustine, MR; maintenance rituximab. 
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Figure S1: Consort diagram summarising study recruitment across the UK and Ireland 
 
 
 
 
Table IS: Therapies used prior to and following idelalisib use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IIS: Univariate predictors of progression or death 
 
A: Univariate predictors of progression or death 
Predictor Hazard ratio (95% CI) P 
FLIPI 0-2 v 3-5 1·88 (0·89 – 3·97) 0·097 
Male gender 0·65 (0·35 - 1·20) 0·172 
ECOG 0-1 vs 2-4 1·16 (0·83 - 1·61) 0·399 
Prior DLBCL 0·39 (0·09 – 1·62) 0·195 
Age > 60 years 0·99 (0·96 - 1·02) 0·420 
LDH > ULN 1·74 (0·92 – 3·28) 0·087 
Lymph node enlargement > 4 areas 1·14 (0·57 – 2·26) 0·360 
Stage III 1·07 (0·36 – 3·14) 0·907 
Therapies prior to Idelalisib use Therapies post Idelalisib use 
First line 
(n = 79) 
Patient 
number 
Second line 
(n = 67) 
Patient 
number 
Third Line 
(n = 47) 
Patient 
number 
Post idelalisib 
(n = 24) 
Patient 
number 
CVP+/-R +/- MR 37 CHOP+/-R +/- MR 15 B+/-R+/- MR 12 Allogeneic SCT 8 (1 additional 
planned 
CHOP+/-R +/- MR 25 B+/-R+/- MR 15 Local 
palliative RT 
8 GEM-based +/-R 4 
Chlorambucil +/- 
prednisolone +/- R 
4 ESHAP +/-R 7 GEM-based 
+/-R 
4 Lenalidomide 2 
BR+/- MR 5 CVP+/-R +/- MR 5 CHOP+/-R 
+/- MR 
7 Steroid based 2 
Other 8 ICE +/-R 5 IVE+/-R 3 Pixantrone (DLBCL) 2 
  IVE+/-R 5 Zevalin+/-R 3 Bendamustine 2 
  DHAP+/-R 4 ESHAP +/-R 3 Local RT 4 
  GEM-based +/-R 5   Clinical trial 2 
  Other 14 Other 12 Other 3 
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Table IIIS: Adverse Events 
Stage IV 1·63 (0·63 – 4·27) 0·317 
Haemoglobin <12 g/dL 0·99 (0·97 – 1·01) 0·296 
Relapsed FL 0·62 (0·35 - 1·15) 0·133 
Prior transplant 1·16 (0·58 - 2·30) 0·681 
Prior lines of treatment 0·98 (0·82 - 1·18) 0·852 
Prior Rituximab Maintenance 1·67 (0·86 – 3·22) 0·128 
 
Adverse Events reported Total number of events 
Neutropenic Fever / Infection 0 
Non-Neutropenic Fever / Infection 
Bronchial Infection 
5 
4 
Haematological 
Neutropenia 
 
3 
Gastroenterological 
Diarrhoea / Colitis 
Hepatitis 
Constipation 
 
5 (all grade 3-4) 
2 (1 grade 1, 1 grade 4) 
1 (grade 2) 
Pneumonitis 4 (1 CMV-induced, and 3 related to idelalisib 
(grade 3 (n = 2), grade 4 (n =1)) 
Cytomegalovirus (CMV) reactivation 
Varicella Zoster virus (VZV) infection 
2 (1 asymptomatic) 
1 
Rash 
Toxic Epidermal necrolysis 
1 
1 
Pyrexia 2 
Others 1 
 
